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SYNTHESIS of IL-I and TNF by human monocytes-
macrophages was significantly inhibited by eleven bisben-
zylisoquinolines and one half-molecule (benzylisoquino-
line), with ICs0 values in thepM range. The results indicate
that these compounds may have value in the therapy of
human diseases where these inflammatory cytokines have
a central role in pathogenesis.
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The pro-inflammatory cytokines interleukin-1
(IL-1) and tumour necrosis factor (TNF) are potent
molecular mediators with wide-ranging effects on a
large array of cells, tissues and organs. 1’2 They are
produced by a wide variety of cell types, but
monocytes-macrophages are the major source of
these polypeptides which share structural similar-
ities and have overlapping activities. 3’4 They have
been implicated in the pathogenesis of chronic
inflammatory (e.g. rheumatoid arthritisS), auto-
immune (e.g. insulin-dependent diabetes melli-
tus6), allergic (e.g. asthma7), infectious (e.g.
leprosys) and malignant (e.g. ovarian carcinoma9)
diseases.
There is therefore a great interest in drugs that
can control their generation and/or action because
of the potential for therapeutic application. It has
recently been shown that tetrandrine, a novel
bisbenzylisoquinoline alkaloid, has potent in-
(C) 1993 Rapid Communications of Oxford Ltd
hibitory effects on the production of IL-lfl and
TNFcz by human monocyte-macrophage cul-
tures.
1-2 In addition, it has been shown to have
therapeutic efficacy in a number of animal models
of human disease, such as relapsing experimental
allergic encephalitis in rats (multiple sclerosis),
13
spontaneous diabetes in BB rats (insulin-dependent
diabetes mellitus),
4 air-pouch inflammation in rats
(rheumatoid arthritis)
is and airways microvascular
leakage in guinea-pigs (asthma).
16 In an attempt to
gain some mechanistic insight into the relationship
between the bisbenzylisoquinoline structure and the
extent of inhibition of the synthesis of TNF-z and
IL-lfl, the inhibitory potencies of tetrandrine and a
series of ten other bisbenzylisoquinolines and one
benzylisoquinoline (half-molecule) are now com-
pared. The bisbenzylisoquinolines vary in the type
of substituent, location of their ether bridges and
the stereochemistry at a chiral centre. The sole
benzylisoquinoline tested is a monomeric compo-
nent of the dimeric benzylisoquinoline, tetrandrine,
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and serves to identify whether the dimeric Shoyaku Company, Tokyo, Japan; berbamineand
bisbenzylisoquinolines are active as a result of their oxyacanthine were purchased from Carl Roth,
inherent macrocyclic structure or because of their Germany; aromoline was isolated from root
constituent functional groups which are also cultures of Stephania cepharantha, as described
present in their smaller monomeric fragments, previously;
2 homoaromoline and obaberine were
converted from aromoline and oxyacanthine,
Materials and Methods respectively, by methylation with diazomethane;
N-methylcoclaurine was prepared by chemical
Compounds: Four types of compounds were used in synthesis.
21
these experiments (Fig. 1). Three of these were All compounds (>97% pure) were identified
macrocyclic ether compounds of isoquinolines for chemical structure by mass spectroscopy and
bridged by alpha-benzyloxy substituents. These 1H-NMR spectroscopy against reference samples
compounds differ in the position of the linkages and literature values.22 The HC1 salts of the
between the two monomeric benzylisoquinoline compounds were dissolved in RPMI 1640 medium
components, and the nature and number of at a concentration of 2 mg/ml, and these stock
substituents on the aromatic rings. The fourth solutions further diluted in RPMI 1640 medium for
type of compound was represented by N- the experiments.
methylcoclaurine, a monomeric benzylisoquinoline.
The twelve compounds used in this study were Production of IL-I[J and TNFe: The study was
obtained from diverse sources.7 Tetrandrine and performed with monocytes-macrophages isolated
fangchinoline, were extracted from the tubers of from human blood.-12 Blood was drawn by
Stephania tetrandra,
8 which were purchased from venepuncture from three healthy non-smoking
Maruzen Seiyaku Company, Onomichi, Japan; adults not on any medication for at least 2 weeks
cepharanoline, cepharanthine, isotetrandrine and prior to the study. The heparinized blood was
cycleanine, extracted from the tuberous root of layered onto Hypaque-Ficoll medium of density
Stephania cepharantha,
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FIG. 1. Chemical structure of the bisbenzylisoquinolines: ten head-to-head conformation (Types A and
B), one head-to-tail (cycleanine) and one half-molecule (N-methvlcoclaurine). Ha and Hb designate
absolute configuration (R or $).
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mononuclear leukocytes (MNC) in the top band at
the interface were harvested,
23 washed and
resuspended in RPMI 1640 medium for the
experiments.
Preparation of adherent MNCs, containing
predominantly monocytes, were made in sterile
plastic Petri dishes. After 3h at 37C, the
non-adherent cells were washed off, and the
adherent cells were later removed with the aid of a
sterile rubber policeman, washed and re-suspended
in RPMI 1640 medium containing 5% foetal calf
serum, and the cell concentration adjusted by
counting in a Neubauer haemocytometer. To 1 ml
of 2 x 106 cells/ml was added 0.5 ml of drug
solution. After incubation at 37C for 15 min,
0.5 ml of 4 x 10: heat-killed, formalin-fixed,
Staphylococcus aureus as a stimulant, were added into
wells of 24-well cluster plates. The supernatants
were harvested after 24 h, and kept frozen at
-70C for up to 2 weeks before being assayed for
the presence of IL-lfl and TNF0. The cells were
checked for viability by Trypan-blue dye exclusion
(>94%).
Quantitation of IL-lfl and TNF: Both IL-1/g and
TNF in the culture supernatants were measured
by a competitive binding radioimmunoassay
(Amersham, UK).
12 The tracer was [12sI]IL-1fl or
TNF0 (human, recombinant), and the antibody to
human recombinant IL-1/3 or TNF was made in
rabbits. The antibody-bound IL-lfl or TNF0 was
then reacted with the Amerlex-M second antibody
reagent (donkey anti-rabbit serum) which contains
a second antibody that is bound to magnetizable
polymer particles. Separation of the antibody-
bound fraction is et:fected by centrifugation of the
Amerlex-M suspension and decantation of the
supernatant. Measurement of the radioactivity in
the pellet enables the amount of labelled IL-1/3 or
TNF0 in the bound fraction to be calculated. The
concentration of unlabelled IL-lfl or TNF0 in the
sample is then determined by interpolation from a
standard curve.
Determination of ICso values: The concentration of
drug (/IM) which causes 50% inhibition of cytokine
production (ICs0) was determined from graphical
plots of inhibitor concentration vs. percentage
inhibition.
Results
Effect on IL- fl andTNF synthesis: Human monocytes-
macrophages were incubated with 0, 1, 4, 10, 20
and 40/lg/ml of each of the twelve compounds. The
results (Table 1) showed dose dependent inhibition
of both IL-lfl and TNF production for all twelve
compounds. Control values (fM/106 cells) for
quantities of IL-1/3 and TNF produced by cultures
were 162.5 + 8.2 and 81.2 ___
4.9 (mean S.E.M.)
respectively, or approximately 2762 and 1380
pg/1/106 cells, respectively.
ICs0 values: The ICs0 values were measured from
graphs of inhibitor concentration vs. % inhibition
and are presented in Table 2. The results show that
all ICs0 values for the twelve compounds are within
the same order ofmagnitude and the range 4-26 #M
and 2-18 #M for IL-lfl and TNF respectively.
Discussion
Currently available drugs for therapy of chronic
inflammatory and autoimmune diseases are un-
satisfactory because of significant toxic and/or
immunosuppressive side effects. There is therefore
a great need to develop better and safer drugs to
control inflammatory tissue destruction. The
discovery of the central role of inflammatory
cytokines in the pathogenesis of these diseases
1-9
opens up a new strategic target for drug
development. The authors recently showed that the
bisbenzylisoquinoline alkaloids, tetrandrine and
berbamine, have the capacity to inhibit both the
generation and action of IL-1/ and TNFo,
1-12 and
control disease progression in a number of animal
models.1>6 Although the mechanism of action of
bisbenzylisoquinolines is not well understood,
studies with tetrandrine have shown its capacity to
block calcium channels,
24 interfere with transmem-
brane signalling,
is and induce apoptosis.
26 More-
over, it is largely devoid of immunosuppressive
properties,2v’28 and is non-toxic at therapeutic doses
(20mg/kg per day for 84 days) as assessed by
appearance, behaviour, weight change, blood
chemistry and organ histology of BB rats.
4 This
compares well with the oral LDs0 of 2 230 mg/kg
in rats,
29 which is more than 100 times the
therapeutic dose. Furthermore, tetrandrine has been
used empirically in humans for the treatment of
silicosis at a dose of 300 mg/day for 3 years without
serious toxic side effects.
3 Thus, bisbenzylisoquino-
lines may have significant advantages over existing
drugs used in the treatment of chronic inflammatory
and autoimmune diseases, such as corticosteroids,
cytotoxic and anti-rejection drugs, which have
substantial toxic and immunosuppressive side
effects. As such, they may become the fore-runner
of a new class of safe and effective drug suitable for
long term clinical usage.
The results of the present study showed that all
eleven bisbenzylisoquinoline alkaloids have in-
hibitory effects on IL-lfl and TNFo synthesis by
human monocytes-macrophages. Calculation of
ICs0 values showed that inhibitory concentrations of
these eleven compounds were within the same order
of magnitude. This was surprising as the structures
depicted in Fig. 1 vary considerably. It was expected
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Table 1. Effect of bisbenzylisoquinolines on production of L-1/t and TNF by human monocytes-macrophages
Drug Concentration Percent of control Drug Concentration Percent of control
(/g/ml) _
S.E.M.) (/g/ml) _+ S.E.M .)
IL-1 TNF IL-1 TNF
Aromoline 89.7 _+ 2.9 86.0 _+ 6.6 Obaberine 95.3 _
5.7 92.6 _+ 2.6
4 71.5 _+ 5.2 75.3 _+ 2.1 4 90.4 _+ 2.6 64.9 +_ 6.8
10 45.7 _+ 5.5 52.1 _
12.2 10 69.0 _+ 3.8 30.2 _+ 5.1
20 20.5 _+ 7.1 39.3 _+ 14.2 20 45.9 _+ 5.6 11.3 _+ 1.5
40 8.2 _+ 3.4 11.7 _+ 3.6 40 13.1 _+ 2.5 4.1 _+ 0.3
Berbamine 87.9 _+ 5.1 77.3 _+ 3.2 Oxyacanthine 101.5 _+ 4.8 100.3 _+ 10.1
4 83.4 _+ 4.8 71.5 _+ 11.0 4 80.9 _
7.9 80.3 _+ 10.6
10 33.7 _+ 11.9 24.0 _+ 12.3 10 37.9 _
12.4 32.2 _+ 3.9
20 7.0 _+ 0.7 3.1 _+ 1.3 20 16.9 _+ 4.2 10.5 _+ 1.1
40 4.3 _+ 1.0 1.5 _+ 1.0 40 5.6_ 0.1 3.2 _
1.3
Cepharanoline 82.4 _+ 7.0 63.3 _+ 8.8 Tetrandrine 84.3 _+ 5.6 72.3 _+ 8.4
4 63.9 _+ 5.0 41.1 _+ 13.7 4 64.9 _+ 4.2 39.6 _+ 6.3
10 40.8_+10.0 23.6_+11.0 10 16.6_+6.0 1.2_+0.7
20 23.0 _+ 8.8 4.5 _+ 0.5 20 13.0 _+ 7.9 1.7 _+ 1.2
40 17.1 _+ 5.7 1.9 _+ 0.9 40 10.1 _+ 6.6 0.3 _+ 0.0
Fangchinoline 94.3 _+ 4.9 91.7 _+ 7.2 Cepharanthine 98.7 _+ 11.2 53.2 _
6.3
4 36.0 _+ 6.3 44.0 _+ 21.2 4 84.4 _+ 7.7 28.7 _+ 1.6
10 3.8 _+ 1.0 2.4 _
0.9 10 49.8 _+ 11.5 10.7 _+ 0.9
20 3.0 _+ 0.9 2.3 _+ 0.8 20 20.5 _+ 5.8 3.1 _+ 1.1
40 1.7 _+ 0.4 1.0 _+ 0.6 40 5.7 _
1.1 2.1 _+ 1.1
Homoaromoline 74.3 _+ 9.5 84.9 _+ 6.3 Cycleanine 84.5 _+ 3.9 74.0 _+ 5.0
4 49.6 _+ 8.9 66.9 _
10.7 4 78.0 _+ 4.2 41.2 _+ 10.8
10 36.4 _
10.8 32.4 _
2.9 10 64.0 _+ 12.6 22.5 _
10.2
20 13.6 _
3.5 7.5 _+ 1.1 20 47.0 _+ 14.1 12.7 _+ 3.5
40 8.1 _
3.1 2.2 _+ 1.56 40 36.6 _+ 8.5 3.3 _+ 1.5
Isoterandrine 73.9 _+ 9.3 75.8 _+ 6.5 N-methyl- 92.6 _+ 9.5 96.6 _+ 3.8
4 70.0 _+ 10.3 43.2 _+ 6.1 coclaurine 4 51.8 _
8.7 82.4 _+ 12.2
10 46.5 _+ 3.3 6.7 _+ 1.1 10 1.5 _+ 3.7 15.2 _+ 6.3
20 12.0 _+ 4.2 1.8 _+ 0.7 20 1.5 _+ 3.0 7.7 _
2.1
40 5.1 +_ 0.8 1.0 _+ 0.9 40 1.6 _+ 3.3 5.5 _+ 1.3
The results represent the mean -t- S.E.M. of three experiments using cells from three individuals. The quantity (fM/106 cells) of IL-1 fl
and TNF produced by control cultures were 162.5 _+ 8.2 and 81.2 _
4.9 (mean _+ S.E.M.), respectively.
Table 2. Inhibition of IL-lfl and TNF production by
bisbenzylisoquinolines" IC5o values
Bisbenzylisoquinolines MW IC5o (/M)
(HCI salts)
IL-I# TNF
Aromoline 667 13.6 18.3
Homoaromol ne 681 8.7 9.8
Oxyacanthine 681 11.6 10.1
Obaberine 695 26.0 8.9
Berbamine 681 11.3 7.3
Isotetrandrine 695 13.4 4.3
Fangchinoline 681 4.6 4.6
Tetrandrine 695 7.2 4.6
Cepharanoline 665 12.3 3.8
Cepharanthine 679 15.0 2.2
Cycleanine 695 25.0 4.6
N-methylcoclaurine* 335.5 11.6 16.4
* half-molecule
that the locations and numbers of methoxy- vs.
hydroxy-substituents (types A and B, cycleanine)
would have significantly influenced interaction with
(unknown) receptors responsible for blocking
synthesis of the specific cytokines in question,
especially if the dimeric form is maintained
intracellularly. Similarly the chirality differences
would lead to different molecular orientations of the
isoquinolines during interaction with receptor(s).
However, the similarity in inhibitor potencies
suggested that the dimer structure as such may not
be the principal activity determinant.
A very significant finding may be that N-
methylcoclaurine, a non-cyclic benzylisoquinoline
quite different from the cyclic bisbenzylisoquino-
lines, has equivalent inhibitory effects on IL-1/ and
TNF production. There are at least two possible
interpretations of these findings in terms of
structure-activity relationships. One interpretation
would be that the bisbenzylisoquinolines and
benzylisoquinolines act on different receptors, even
though both are equipotent inhibitors of inflam-
matory cytokine production. A more likely in-
terpretation is that the monomers, benzylisoqui-
nolines, may be the active forms of the
bisbenzylisoquinolines. Bisbenzylisoquinolines like
N-methylcoclaurine are known to chemically
assemble in plants to form bisbenzylisoquinolines
like tetrandrine. However, it is not known whether
bisbenzylisoquinolines transform biologically into
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monomeric benzylisoquinolines, although it has
been shown chemically that cleavage of tetrandrine
can be achieved using strong reducing conditions
(metallic sodium in liquid ammonia) into two
monomers, one of which is N-methylcoclaurine.
31
One avenue for further investigation would be
to determine whether the bisbenzylisoquinolines are
metabolized under the conditions of these experi-
ments and, if so, to identify the metabolites after in
vitro and in vivo degradation. Another would be to
determine whether bisbenzylisoquinolines and
benzylisoquinolines have similar or different mo-
lecular modes of actions. Because of the importance
of" inflammatory cytokines in health and disease,
further development of these classes of compounds
may provide insights into the biology of inflam-
matory cytokines as well as to a better and safer
drug for therapy of inflammatory diseases.
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